MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.270
+0.020
+1.60%
Closed 16:00 03/31 EDT
OPEN
1.290
PREV CLOSE
1.250
HIGH
1.290
LOW
1.220
VOLUME
23.46K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
1.039
MARKET CAP
28.90M
P/E (TTM)
-0.3183
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONCS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONCS stock price target is 7.50 with a high estimate of 9.00 and a low estimate of 6.00.

EPS

ONCS News

More
  • OncoSec Medical Incorporated to Present at the New York City based Investor Summit on March 25th-26th
  • ACCESSWIRE · 03/20 14:00
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • OncoSec Announces Publication of Positive TAVO Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncology
  • PR Newswire · 03/17 13:30
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52

Industry

Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About ONCS

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
More

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.